RT Journal Article
SR Electronic
T1 Predictive and analysis of COVID-19 cases cumulative total: ARIMA model based on machine learning
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.24.22269791
DO 10.1101/2022.01.24.22269791
A1 Yan, Zehui
A1 Wang, Yanding
A1 Yang, Meitao
A1 Li, Zhiqiang
A1 Gong, Xinran
A1 Wu, Di
A1 Zhang, Wenyi
A1 Wang, Yong
YR 2022
UL http://medrxiv.org/content/early/2022/01/30/2022.01.24.22269791.abstract
AB At present, COVID-19 poses a serious threat to global human health, and the cumulative confirmed cases in America, Brazil and India continue to grow rapidly. Therefore, the prediction models of cumulative confirmed cases in America, Brazil and India from August 1, 2021 to December 31, 2021 were established. In this study, the prevalence data of COVID-19 from 1 August 2021 to 31 December 2021 were collected from the World Health Organization website. Several ARIMA models were formulated with different ARIMA parameters. ARIMA (7,2,0), ARIMA (3,2,1), and ARIMA (10,2,4) models were selected as the best models for America, Brazil, and India, respectively. Initial combinations of model parameters were selected using the automated ARIMA model, and the optimized model parameters were then found based on Bayesian information criterion (BIC). The analytical tools autocorrelation function (ACF), and partial autocorrelation function (PACF) were used to evaluate the reliability of the model. The performance of different models in predicting confirmed cases from January 1, 2022 to January 5, 2022 was compared by using root mean square error (RMSE), mean absolute error (MAE), and mean absolute percentage error (MAPE). This study shows that ARIMA models are suitable for predicting the prevalence of COVID-19 in the future. The results of the analysis can shed light on understanding the trends of the outbreak and give an idea of the epidemiological stage of these regions. Besides, the prediction of COVID-19 prevalence trends of America, Brazil, and India can help take precautions and policy formulation for this epidemic in other countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was fully funded by National Major Science and Technology of China (2018ZX107130003) and The National Natural Science Foundation of China (12031010).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccording to the reasonable requirements of the author, all the data generated in this study can be obtained. All the data generated in the current work are included in the manuscript, and all the data generated can be consulted online. https://www.who.int/emergencies/disease-outbreak-news